Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus

JAMA Internal Medicine

Volumn 176, Issue 10, 2016, Pages 1474-1481

  Faillie, Jean Luc ^a,b   Yu, Oriana H ^c,d   Yin, Hui ^a,c   Hillaire Buys, Dominique ^b,e   Barkun, Alan ^f   Azoulay, Laurent ^c,g  

^a UNIV MONTPELLIER   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e INSERM   (France)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; GLUCAGON LIKE PEPTIDE 1;

ADULT; ARTICLE; BILE DUCT DISEASE; CHOLANGITIS; CHOLECYSTECTOMY; CHOLECYSTITIS; CHOLELITHIASIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GALLBLADDER DISEASE; HOSPITAL PATIENT; HUMAN; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SECONDARY ANALYSIS; SENSITIVITY ANALYSIS; ANALOGS AND DERIVATIVES; BILE DUCT DISEASES; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; GALLBLADDER DISEASES; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM;

ADULT; BILE DUCT DISEASES; CHOLECYSTECTOMY; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GALLBLADDER DISEASES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; PROPORTIONAL HAZARDS MODELS; UNITED KINGDOM;

EID: 84997171051     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.1531     Document Type: Article

References (28)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596.
2. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122(2):531-544.
3. Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007; 133(1):244-255.
4. Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut. 2009;58(7):990-997.
5. VigiLyze. Search and analysis tool for VigiBase the WHO global ICSR (Individual Case Safety Report) database. https://vigilyze.who-umc.org/. Accessed December 21, 2015.
6. Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.
7. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998; 45(5):419-425.
8. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836.
9. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4-14.
10. Kimura Y, Takada T, Kawarada Y, et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14 (1):15-26.
11. Bates GC, Brown CH. Incidence of gallbladder disease in chronic hemolytic anemia (spherocytosis). Gastroenterology. 1952;21(1): 104-109.
12. Bond LR, Hatty SR, Horn ME, Dick M, Meire HB, Bellingham AJ. Gall stones in sickle cell disease in the United Kingdom. Br Med J (Clin Res Ed). 1987; 295(6592):234-236.
13. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
14. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2): 138-147.
15. Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174 (5):613-620.
16. Davies MJ, Bergenstal R, Bode B, et al; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687-699.
17. Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12(12):1347-1352.
18. Everhart JE. Contributions of obesity and weight loss to gallstone disease. Ann Intern Med. 1993;119(10):1029-1035.
19. US Food and Drug Administration (FDA). Liraglutide 3.0mg for weight management NDA 206-321 briefing document. Endocrinologic and Metabolic Drug Advisory Committee. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm413318.pdf. Published September 11, 2014. Accessed December 21, 2015.
20. Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1-3):77-83.
21. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1)(suppl):S3-S18.
22. Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med. 2011;123(6):189-201.
23. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2): 194-206.
24. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: ameta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909-917.
25. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167 (4):492-499.
26. Haffner SM, Diehl AK, Valdez R, et al. Clinical gallbladder disease in NIDDM subjects. Relationship to duration of diabetes and severity of glycemia. Diabetes Care. 1993;16(9):1276-1284.
27. Health & Social Care Information Centre. Read codes. http://systems.hscic.gov.uk/data/uktc/readcodes. Accessed March 31, 2016.
28. National Health Service. Dictionary of Medicines and Devices. http://www.nhsbsa.nhs.uk/PrescriptionServices/1121.aspx. Accessed March 31, 2016.